Group 5F: HR+ Breast Cancer; Clinical Trials; Hormone Therapies; Targeted Therapies; Treatment Resistance
Poster #TPS1118: A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1)
Poster #1057: Lasofoxifene (LAS) plus abemaciclib (Abema) for treatingĀ ESR1-mutated ER+/HER2- metastatic breast cancer (mBC) after progression on prior therapies: ELAINE 2 study update
Sold out!
